J. Goldman & Co LP acquired a new position in shares of Clementia Pharmaceuticals Inc (NASDAQ:CMTA) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,692 shares of the company’s stock, valued at approximately $488,000. J. Goldman & Co LP owned 0.08% of Clementia Pharmaceuticals as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of CMTA. Victory Capital Management Inc. acquired a new stake in Clementia Pharmaceuticals in the third quarter worth $520,000. Sphera Funds Management LTD. acquired a new stake in Clementia Pharmaceuticals in the third quarter worth $2,753,000. JPMorgan Chase & Co. acquired a new stake in Clementia Pharmaceuticals in the third quarter worth $10,937,000. Citadel Advisors LLC acquired a new stake in Clementia Pharmaceuticals in the third quarter worth $2,061,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Clementia Pharmaceuticals in the third quarter worth $1,351,000. Institutional investors own 68.04% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $27.00.
TRADEMARK VIOLATION NOTICE: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3293806/j-goldman-co-lp-acquires-shares-of-25692-clementia-pharmaceuticals-inc-cmta.html.
Clementia Pharmaceuticals Company Profile
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.